Clinical trials: Alteplase
Ischemic Stroke, Stroke
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
The primary goal of this trial is to determine if individuals with acute ischemic stroke treated with a medium dose of IV rt-PA plus IV eptifibatide started within 3 hours of symptom onset are more likely to have a better outcome…
- Conditions
- Ischemic Stroke, Stroke, Brain Infarction
- Trial name
- CLEAR-ER (NCT00894803)
- Testing
- Eptifibatide, rt-PA
- Where
- 20 sites in United States
- Volunteers
- 126 people
- Sponsor
- University of Cincinnati
Stroke, Ischemic Stroke
Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke
This pilot trial will be the first step toward direct comparison of delivery of endovascular reperfusion therapy to intravenous recombinant tissue plasminogen activator (rt-PA) in a time-to-treatment framework shown as most…
- Trial name
- EARLY (NCT01869478)
- Testing
- Intravenous Thrombolysis, Endovascular Arterial Reperfusion
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Ischemic Stroke
Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery
To assess the safety and preliminary efficacy of combining intravenous rt-PA with transcranial laser therapy (TLT) with the NeuroThera® Laser System (referred to hereafter as NTS) in subjects treated for acute ischemic stroke.
- Trial name
- StELLAR (NCT01220739)
- Testing
- Transcranial Laser Therapy
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Diego
Stroke
Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)
The purpose of this study is to determine which of 3 different doses of tenecteplase (TNK) is better for treating stroke patients and if TNK offers an advantage over currently available treatment with tissue plasminogen activator…
- Trial name
- NCT00252239
- Testing
- tenecteplase, tissue plasminogen activator, tPA
- Where
- 9 sites in United States
- Volunteers
- 112 people
- Sponsor
- University of Virginia
COVID
Nebulised Rt-PA for ARDS Due to COVID-19
Some patients infected with COVID-19 develop a severe form of a lung disease called acute respiratory distress syndrome (ARDS). In these patients, the lungs become severely inflamed because of the virus.
- Trial name
- PACA (NCT04356833)
- Testing
- Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- University College, London
Obesity
Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3
The purpose of the study is to determine if giving isosorbide,a drug that is used to treat chest pain, affects blood vessel release of an anti-clotting factor.
- Trial name
- NCT00685945
- Testing
- Control (bradykinin), L-NMMA + bradykinin, Isosorbide + L-NMMA + bradykinin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Pleural Infection, Empyema
Fibrinolysis Compared to Thoracoscopy for Pleural Infection
The purpose of this prospective randomized clinical trial is to compare two currently accepted standard-of-care treatment strategies: Medical thoracoscopy as compared to instillation of intrapleural tissue Plasminogen Activator…
- Conditions
- Pleural Infection, Empyema, Pleural Diseases, Parapneumonic Effusion
- Trial name
- NCT03468933
- Testing
- tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase), Medical Thoracoscopy
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Tulane University
Ischemic Stroke
Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
The aim of the study is to determine if single-bolus recombinant nonimmunogenic staphylokinase is effective and save thrombolytic agent in patients with ischemic stroke in comparison to alteplase.
- Trial name
- NCT03151993
- Testing
- Recombinant staphylokinase, Alteplase
- Where
- 18 sites in Russia
- Volunteers
- 336 people
- Sponsor
- Supergene, LLC
Stroke
1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients
The objective of the study is to find out the 1-year clinical outcomes among Acute Ischaemic Stroke (AIS) patients who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of…
- Trial name
- NCT05395338
- Testing
- rt-PA
- Where
- China
- Volunteers
- 12,551 people
- Sponsor
- Boehringer Ingelheim
Stroke
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）
The purpose of this study is to confirm the efficacy and safety of intravenously administered alteplase in patients with acute ischemic stroke based on the rate of recanalization assessed by magnetic resonance angiography (MRA)…
- Trial name
- NCT00412867
- Testing
- Alteplase
- Where
- Japan
- Volunteers
- 58 people
- Sponsor
- Tanabe Pharma Corporation
Acute Stroke
A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients
This study was jointly developed and is jointly led by investigators at Massachusetts General Hospital and the intramural division of NINDS.
- Trial name
- MR WITNESS (NCT01282242)
- Testing
- IV rt-PA
- Where
- 14 sites in United States
- Volunteers
- 88 people
- Sponsor
- Lee Schwamm
Abdominal Abscess, Pelvic Abscess
Alteplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses
Intracavitary injection of low dose alteplase into loculated abdominopelvic abscesses will reduce the duration of percutaneous drainage and increase the proportion of successful drainages.
- Trial name
- NCT00284739
- Testing
- Alteplase, saline
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kaiser Permanente
Acute Deep Venous Thrombosis of the Lower Extremity
Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins
This study will test the effectiveness of low-dose recombinant tissue plasminogen activator (rtPA, or alteplase) in dissolving blood clots in deep leg veins.
- Trial name
- NCT00082355
- Testing
- Alteplase (Activase, Genentech)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Richard Chang, M.D.
Pulmonary Embolism, Acute Pulmonary Embolism
Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
The purpose of this study is to determine if the EKOS EkoSonic® Endovascular Device when used in conjunction with recombinant tissue plasminogen activator (t-PA) as a treatment for acute PE will decrease the ratio of right…
- Conditions
- Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism, Massive Pulmonary Embolism
- Trial name
- SEATTLE II (NCT01513759)
- Testing
- recombinant tissue plasminogen activator, EKOS EkoSonic Endovascular System
- Where
- 22 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Obesity
Characterization of Brachial Arterial t-PA Release, Endothelial Function, Obesity and Inflammation
T-PA release is impaired in obese subjects. In order to have a better mechanistic understanding of t-PA release, we will compare t-PA release to Flow Mediated Vasodilation, Radial Artery Tonometry, and other markers of…
- Trial name
- P1A3B (NCT00780481)
- Testing
- Bradykinin
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Stroke, Acute
Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke
The primary aim of this study is to find out which of 4 different doses of minocycline are safe and well tolerated so that we will know the optimal dose to test in future patients.
- Trial name
- MINOS (NCT00630396)
- Testing
- Minocycline
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- David Hess, MD
Catheter Obstruction, Vascular Access Devices
Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion
This is a multicentre, open-label, randomised, phase III study designed to evaluate the efficacy and safety of Actilyse 2 mg/2 ml in the restoration of function of CVAD
- Trial name
- NCT01958164
- Testing
- Actilyse, Saline solution
- Where
- 5 sites in Russia
- Volunteers
- 16 people
- Sponsor
- Boehringer Ingelheim
Pleural Empyema
Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)
Bacterial pneumonia can be complicated by the development of excess fluid and pus (pleural empyema) around the lungs in children. The incidence of pleural empyema in children has increased significantly in the last 10 years.
- Trial name
- NCT01717742
- Testing
- TPA (Tissue Plasminogen Activator), DNase
- Where
- 6 sites in Canada
- Volunteers
- 97 people
- Sponsor
- The Hospital for Sick Children
Stroke
Thrombolytic Care During Inter-hospital Transfer
Evaluation of ischemic stroke patients receiving tissue plasminogen activator (rtPA) during air ambulance transfer
- Trial name
- NCT02752256
- Testing
- Tissue Plasminogen Activator
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Ischemic Stroke
Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic stroke is caused by a blood clot that blocks the flow of blood to the brain and damages brain cells. The clot, or thrombus, is made up of platelets and fibrin.
- Trial name
- CATALIST (NCT00061373)
- Testing
- Aspirin, tinzaparin sodium, eptifibatide
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)